Skip Ribbon Commands
Skip to main content
Navigate Up

Drug Discovery

Listed below are brief descriptions of the CAMH drug development platform that is available for licensing. Follow the links to read a non-confidential summary of each technology. 
 
Feel free to contact our office should you require more information or wish inquire about the first steps in securing a licensing deal.

 

Innovative Drug Development Platform for Brain Disorders


Brief Description:
CAMH investigators in collaboration with a multi-disciplinary team have developed an early-stage drug discovery platform. To accelerate the translation of basic science findings into clinically useful drugs, they have proposed an accelerated drug development model that will allow for Fast-Try/Fast-Fail of lead targets and compounds. Necessary steps can be summarized as such: (1) target identification, (2) lead compound identification, (3) pre-clinical validation, (4) target engagement assay development in humans, (5) intellectual property portfolio development, (6) toxicology studies (animals and humans), and finally (7) proof of concept clinical trial in a stratified population (based on genetics and target engagement) (i.e., Phase 2a). The most advanced target and compound leads to date focus on augmenting signaling at Alpha5-containing GABAA receptors. This accelerated drug development model provides a more efficient process and pipeline to translate basic sciences into drug development. See the detailed summary.

 

 Related Information

 
CAMH Switchboard 416-535-8501
CAMH General Information Toronto: 416-595-6111 Toll Free: 1-800-463-6273
Connex Ontario Help Lines
Queen St.
1001 Queen St. W
Toronto, ON
M6J 1H4
Russell St.
33 Russell St.
Toronto, ON
M5S 2S1
College St.
250 College St.
Toronto, ON
M5T 1R8
Ten offices across Ontario